Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Titel:
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Auteur:
Roberts, John D. Shibata, Stephen Spicer, Darcy V. McLeod, Howard L. Tombes, Mary Beth Kyle, Brenda Carroll, Mary Sheedy, Beth Collier, Mary A. Pithavala, Yazdi K. Paradiso, Linda J. Clendeninn, Neil J.